Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922032 | 1.00 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8570280 | 0.75 | POLB (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2921409 | 0.73 | — | — | |
| SCHEMBL2268664 | 0.73 | — | — | |
| SCHEMBL2267011 | 0.73 | — | — | |
| SCHEMBL27406050 | 0.72 | DPP4 (0.33) | DPP4 | |
| SCHEMBL8644149 | 0.72 | DPP4 (0.33) | DPP4 | |
| SCHEMBL23872426 | 0.71 | DPP4 (0.34) | DPP4 | |
| SCHEMBL23872424 | 0.71 | DPP4 (0.34) | DPP4 | |
| SCHEMBL9469864 | 0.71 | DPP4 (0.38) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481709-B2 | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism | OBE THERAPY BIOTECHNOLOGY (FR) | 2016-11-01 | — | — | US | disclosed |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2010-12-09 | — | — | US | disclosed |
| EP-2225261-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071601-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, ANPEP | CHRM2 3842/4885CHRM4 3641/4885CHRM5 3451/4885 |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, FABP4 | CHRM2 4143/4885CHRM4 3742/4885CHRM5 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.